ArticleScientific reports2025
Screening biomarkers related to cholesterol metabolism in osteoarthritis based on transcriptomics.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholesterol metabolism-related genes (CMRGs) have been associated with osteoarthritis (OA), but their specific regulatory mechanisms remain unclear. This study aimed to investigate the role of CMRGs in OA and provide new insights into its treatment. In this study, two OA datasets, GSE55457 and GSE55235, were applied, which contained the transcriptome data of 10 OA samples and 10 control samples (synovial tissue) respectively. Using these two OA datasets and CMRGs, 21 candidate genes were identified by overlapping CMRGs and differentially expressed genes (DEGs). Protein-protein interaction networks were constructed, revealing interactions among candidate genes. Three machine learning algorithms identified ATF3, CHKA, CLU, CTNNB1, and FASN as potential biomarkers. Further evaluation in two datasets confirmed ATF3, CLU, and FASN as biomarkers, with quantitative reverse transcription polymerase chain reaction (qRT-PCR) results showing elevated CLU and decreased ATF3 and FASN expression in OA. Receiver operating characteristic (ROC) curves and a nomogram model demonstrated high accuracy in predicting OA. Among them, in the GSE55457 dataset, the Area Under the Curve (AUC) value of ATF3 was 0.78 (95% CI 0.71-0.85), the AUC value of CLU was 0.82 (95% CI 0.75-0.89), and the AUC value of FASN was 0.76 (95% CI 0.69-0.83). The AUC value of the nomogram model based on these biomarkers in the training set was 0.90 (95% CI 0.80-0.90), and the slope of the calibration curve was close to 1. Immunocorrelation analysis revealed favorable correlations between ATF3, FASN, and immune cell activities. In conclusion, ATF3, CLU, and FASN were identified as cholesterol metabolism biomarkers in OA, offering new perspectives on the relationship between CMRGs and OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.